In a recent analysis, Emergen Research predicted that by 2027, the global market for newborn screening would generate $2.27 billion in revenue.
In a recent analysis, Emergen Research predicted that by 2027, the global market for newborn screening would generate $2.27 billion in revenue. Infants undergo newborn screening exams to look for developmental, metabolic, and genetic anomalies. There are more than 30 diseases and disorders covered by newborn screening. Additionally, a number of nonprofit and governmental organisations are mainly concentrating on offering high-quality foetal and maternal care. In addition, the government agencies involved in coordinating awareness and quality control initiatives to foster confidence and reduce the number of deaths brought on by negligence and non-screening are predicted to increase demand for the business. The addition of autoimmune illnesses as potential candidates in NBS programmes has been made possible by new treatments such enzyme replacement therapy, hematopoietic stem cell transplant, gene therapy, and innovative therapeutic medicines.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/4
Growing newborn screening programmes, rising congenital illness rates, securing financing from government sectors for newborn screening, and improvements in technologies utilised in newborn screening are all contributing factors to the market’s expansion. According to the Heart Disease and Stroke Statistical Fact Sheet 2020, congenital heart abnormalities are predicted to impact at least 40,000 infants in the United States each year. It is anticipated that about 25% (2.4 per 1,000 live births) of the affected children will need medical attention in the first year of life. As a result, the market is anticipated to develop as more newborn screening tests are used.
The sector for newborn screening is anticipated to benefit from the introduction of cutting-edge screening technologies and ensuing therapeutic approvals. Additionally, the market for newborn screening is anticipated to rise as congenital cardiac illnesses and genetic disorders become more common in newborns. The primary constraints that can impede the growth of the newborn screening market are the lack of parental knowledge about neonatal screening, the scarcity of skilled practitioners, and the lack of precision in certain of the tests.
Some Key Highlights from the Report
- Due to the enormous demand for DBS newborn screening tests brought on by the COVID-19 pandemic, new NBS tests have been developed throughout the epidemic. With the ability to handle up to 5,000 samples per day, PerkinElmer Inc. introduced a dry blood spot (DBS) based test for SARS-CoV-2 IgG in July 2020 utilising their GSP/DELFIA platform. In 32 different nations throughout the world, the DBS assay, which uses PerkinElmer’s GSP analyzer and the TRF (time-resolved fluorescence) of the DELFIA platform, screens more than 30% of all newborn infants.
- During the predicted period, dried blood spot tests (DBS) are anticipated to maintain their dominance. Since more than 50 years ago, DBS sampling has been used to check newborns for congenital metabolic disorders. The benefits of DBS sampling include its low volume demands (about 30 to 100 L per location), convenience of sample collection with a finger or heel stick with little training needed, and sample stability and portability. This test can be used to identify several different metabolic diseases, including autism, lymphomas, and leukaemia. Dried blood spot analysis has the benefit of only requiring a tiny sample size that is portable. Thus, the increase in infant illnesses is fueling market expansion.
Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/new-born-screening-market
- Based on technology, electrophoresis brought in USD 0.15 billion in revenue in 2019, and it is anticipated that this figure will increase with a CAGR of 11.1 percent over the course of the forecast period due to rising demand and new detection techniques that help identify amino acids, carnitine conjugates, and other compounds.
- Due to its wide range of classes, including enzymatic assay kits, DNA assay kits, immunoassay kits, and others—among which immunoassay is a process-oriented employed in the screening—the assay kits are anticipated to rise with a CAGR of 10.4% in the forecasted period.
- The Newborn Screening Market is primarily driven by the dry blood spot test application. The market’s largest stakeholder, the dry blood spot test application from the North American area, held around 43.1% of the market in 2019.
- The newborn screening industry is dominated by North America, and this dominance is anticipated to last for a few more years. Congenital disorders are becoming more common, and testing is required in all 50 states of the union. The United States has the greatest market share in North America. This is due to both the expanding need for sophisticated systems and the rising incidence rates of diseases in neonates.
- Key players include AB Sciex LLC, Covidien Plc, Masimo Corp., GE Healthcare, Waters Corp., Trivitron Healthcare, Natus Medical Inc., PerkinElmer Inc., Agilent Technologies Inc., and others.
Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/4
For the purpose of this report, Emergen Research has segmented the global Newborn Screening Market on the basis of Technology, Product, Application, and region:
Technology Outlook (Revenue, USD Billion; 2017-2027)
- Tandem Mass Spectrometry
- Pulse Oximetry
- Enzyme Based Assay
- DNA Assay
- Electrophoresis
- Others
Product Outlook (Revenue, USD Billion; 2017-2027)
- Instruments
- Reagents
- Assay Kits
- Others
Application Outlook (Revenue, USD Billion; 2017-2027)
- Dry Blood Spot Test
- Critical Congenital Heart Disease (CCHD)
- Hearing Screen
- Others
Regional Outlook (Revenue, USD Billion; 2017-2027)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- BENELUX
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- MEA
- Saudi Arabia
- UAE
- Rest of MEA
Make an Inquiry Before Buying@ https://www.emergenresearch.com/purchase-enquiry/4
Explore More Reports Emergen Research:
Hemodynamic Monitoring Devices Market
Near Infrared Spectroscopy Market
Nerve Repair and Regeneration Market
Next Generation Implants Market
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trend’s existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Emergen Research Media Citations: https://www.emergenresearch.com/media-citations
Visit for More Insights: https://www.emergenresearch.com/insights
Explore Our Custom Intelligence services | Growth Consulting Services
Press Release Available @ https://www.emergenresearch.com/press-release/global-newborn-screening-market